The FDA approved betibeglogene autotemcel (beti-cel; Zynteglo) for adult and pediatric patients with transfusion-dependent ...
Global Thalassemia Market Global Thalassemia Market Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Thalassemia Market by ...
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...
The therapy involves taking stem cells out of a patient's bone marrow and editing a gene in the cells in a laboratory and ...
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...
Known as Zynteglo in Europe where it is approved to treat the rare blood disorder beta-thalassemia, the gene therapy has been given the all-clear by bluebird’s scientists after reviewing the ...
"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...
Despite these changes, Editas Medicine reported preclinical success in hematopoietic stem cells gene editing, a potential treatment for sickle cell disease and beta thalassemia. Several analyst ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback